StemCells, Inc. Initiates World’s First Neural Stem Cell Trial in Spinal Cord Injury

3/24/2011 12:00:00 AM

StemCells, Inc. (Nasdaq:STEM) announced today the initiation of a Phase I/II clinical trial of its proprietary HuCNS-SC(R) human neural stem cells in chronic spinal cord injury. This trial is now open for enrollment, and will accrue patients with both complete and incomplete degrees of paralysis who are three to 12 months post-injury. The trial is being conducted in Switzerland at the Balgrist University Hospital, University of Zurich, a world leading medical center for spinal cord injury and rehabilitation, and is being led by Armin Curt, MD, Professor and Chairman, Spinal Cord Injury Center at the University of Zurich, and Medical Director of the Paraplegic Center at the Balgrist University Hospital.

Dr. Curt stated, “The launch of this trial is truly a landmark event for the field of spinal cord injury research. For patients facing a lifetime of paralysis, the prospect that neural stem cell transplantation may one day help restore some degree of function offers new hope. What is particularly exciting to me is the innovative design of this trial. Within the setting of one trial, we will progress from the most severely injured to less severely injured. In addition to our primary focus on assessing safety, the design of the trial will afford a very real near-term opportunity to observe possible benefits to the patient, which may include improved sensation, motor function, bowel or bladder function. I am extremely pleased to be involved in a study that is breaking barriers in the search for a treatment that could lead to improved quality of life for injured patients.”

Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc., added, “Dr. Curt is an internationally renowned expert in spinal cord injury, and we look forward to working with him and his team of experienced investigators at Balgrist. Our HuCNS-SC cells have shown significant promise in preclinical studies for restoring lost motor function, and we are excited to take this important first step toward our goal of developing a neural stem cell therapy that could offer similar benefits for patients living with paralysis. We plan to enroll the first cohort of patients with complete injury this year, and will then transition to patients with incomplete injuries early next year.”

About the Trial

The trial is designed to assess both safety and preliminary efficacy. The trial will enroll 12 patients with thoracic (chest-level) spinal cord injury who have a neurological injury level of T2-T11, and will include both complete and incomplete injuries as classified by the American Spinal Injury Association (ASIA) Impairment Scale. The first cohort will be patients classified as ASIA A, or patients who have what is considered to be a “complete” injury, or no movement or feeling below the level of the injury. The second cohort will progress to patients classified as ASIA B, or patients with some degree of feeling below the injury. The third cohort will consist of patients classified as ASIA C, or patients with some degree of movement below the injury. In addition to assessing safety, the trial will measure defined clinical endpoints, such as changes in sensation, motor, and bowel/bladder function. All patients will receive HuCNS-SC cells through direct transplantation into the spinal cord, and will be temporarily immunosuppressed. Following transplantation, the patients will be evaluated regularly over a 12-month period in order to monitor and evaluate the safety and tolerability of the HuCNS-SC cells, the surgery and the immunosuppression, and to measure any recovery of neurological function below the injury site. As the Company intends to follow the effects of this therapy long-term, a separate four-year observational study will be initiated at the conclusion of this trial. For information on patient enrollment, interested parties may contact the study nurse either by phone at +41 44 386 39 01, or by email at stemcells.pz@balgrist.ch.

Additional information about the Company’s spinal cord injury program can be found on the StemCells, Inc. website at http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm and at http://www.stemcellsinc.com/Therapeutic-Programs/Spinal-Cord-Injury.htm, including video interviews with Company executives and independent collaborators.

About Chronic Spinal Cord Injury

Chronic spinal cord injury is characterized as a continuum of time after injury, which starts when inflammation has stabilized and behavioral recovery is reaching a plateau. The chronic phase typically does not set in until several months following the injury. To date, treatment approaches for neural repair and regeneration have generally targeted the acute and sub-acute time points, which are considered to be hours or days following injury. Restoring some degree of function for patients at later time points beyond the acute recovery phase could have a transformative impact on the field as there are no effective treatment options for these patients today. StemCells hopes to address a broad population of spinal cord-injured patients by opening the window of opportunity for therapeutic intervention to months or longer post-injury, and by targeting a wide range of injury levels and degrees of impairment.

About HuCNS-SC Cells

StemCells’ lead product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. The Company’s preclinical research has shown that HuCNS-SC cells can be directly transplanted in the central nervous system (CNS) with no sign of tumor formation or adverse effects. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, this suggests the possibility of a durable clinical effect following a single transplantation. StemCells believes that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the CNS, and to date has demonstrated human safety data from completed and ongoing studies of these cells in two fatal brain disorders in children.

About Balgrist University Hospital

Balgrist University Hospital (www.balgrist.ch) is recognized worldwide as a highly specialized, leading center of excellence providing examination, treatment and rehabilitation opportunities to patients with serious musculoskeletal conditions. The clinic owes its first-rate international reputation to its unique combination of specialized medical services. The hospital’s carefully-balanced, interdisciplinary network brings together medical specialties ranging from orthopedics, paraplegiology, radiology and anesthesiology to rheumatology and physical medicine under one roof.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. In its therapeutic product development programs, StemCells is targeting disorders of the central nervous system and the liver. StemCells’ lead product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in clinical development for spinal cord injury and two fatal neurodegenerative disorders in children, and in preclinical development for retinal disorders such as age-related macular degeneration. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.



 News from National  

Get the latest news, resources and information from our national affiliate, United Spinal Association.



  Our Mission

The Mission of the Connecticut Spinal Cord Injury Association (SCIACT), a chapter of United Spinal Association, is to support those with spinal related injuries or diseases and their families by being an advocate for their rights while serving as a resource to its members and the general public.

Learn More

 More stories in sci_news

  Rehab service helps people in CT with challenges obtain driver’s license

Go To Article...

  35,000 Private Home Care Workers to Have Contact Information Made Public in State Regulatory Push

Go To Article...

  A study in chronic pain: are you eligible?

Read More...

  Wheelchair Assessment: Bringing Technologies and Users Together

Go To Article...

  Barbie introduces dolls with wheelchairs and prosthetic limbs

Go To Article...

  Full Body Winter Coat Designed for Wheelchair Users!

Go To Article...

  New O’Hare restroom more accessible than any other in U.S., officials say

Go To Article...

  ABC's 'Speechless' Calls for Abilities Expo

Go To Article...

  Time to get out and vote - make it count for disabilities!

Read More...

  Electrical implant helps paralyzed patients walk again

Go To Article...

  Paralyzed During Vacation: 'I'm Happier Than I've Ever Been'

Go To Article...

  Report Disabled Parking Abuse with the Parking Mobility App

Go To Article...

  UConn Says No To Wheelchair Basketball Team In Fall 2018

Go To Article...

  General Assembly approves raises for home-care workers

Go To Article...

  Paralyzed Ex-UConn Basketball Player Now a Curling Paralympian

Go To Article...

  Wheelchair Basketball Clinic Raises Hopes For Intercollegiate Program At UConn

Go To Article...

  Scientists May Have Discovered How Spinal Injuries Are Repaired On a Cellular Level

Go To Article...

  Independent living centers at risk from state, federal budget cuts

Go To Article...

  Ed Roberts activist Google Doodle honors leader of the disability rights movement

Go To Article...

  People with SCI Wanted for Rowing-Based Exercise Study

Read More...

  New science helps a paralyzed man move his legs for the first time in years

Go To Article...

  Olympic Swimmer Amy Van Dyken Determined to Walk Again

Go To Article...

  Man With Severed Spine Walks Again in 'World First'

Go To Article...

  Paraplegic in an exoskeleton opens the World Cup -- with a kick

Go To Article...

  Stimulation restores some function for 4 paralyzed men

Go To Article...

  Repair Stem Cells Institute Announces "Double Benefits for SCI" Stem Cells Treatment

Read More...

  Tobii EyeMobile: Control Windows 8 tablets using only your eyes

Go To Article...

  Adaptive Snowboarding and Other Winter Sports

Go To Article...

  TEK Robotic Mobilization Device: designed to replace wheelchairs

Go To Article...

  Tongue piercing lets paralyzed drive wheelchairs

Read More...

  Senate Bill Introduced To Create Separate Benefit Category for Complex Rehab Technology

Read More...

  Ekso Bionics' robotic suit eyes-on (video)

Go To Article...

  NCART: Schumer to Introduce Senate Bill for Separate Benefit Category

Go To Article...

  All-terrain chairs open doors

Go To Article...

  Nobel Winners Unlocked Cells Unlimited Potential

Go To Article...

  UK Paraplegic Woman Uses Robotic Suit to Walk

Go To Article...

  SCI Total Fitness Program Breaks Down the Barriers of Exercise For People with Spinal Cord Injury

Read More...

  Paralyzed Rats Learn to Walk Again In Rehabilitation Experiment

Go To Article...

  Compressed Natural Gas Fueling Station Opens at Metro Taxi

Read More...

  Landmark Spinal Repair Stem Cell Trial

Read More...

  Lack Of Accessible Cabs Doesn’t Sit Well With Senator

Read More...

  More Than Walking: filmaker's SCI joureny

Read More...

  StemCells, Inc. Initiates World’s First Neural Stem Cell Trial in Spinal Cord Injury

Read More...

  First patient treated in embryonic stem cell trial

Go To Article...

  Robotic Legs Get Wheelchair Users Walking

Go To Article...

  Paralyzed Rats Walk Again

Go To Article...



  Donate

Donating to the SCIACT has never been easier or more secure! Please click this button to donate the amount of your choice using your PayPal account or any major credit card.

Learn More